NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/06/2026 10:12
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization8.5 mln
Earnings Date06/19/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-5.79
Highly reliable
Relative Strength
76
/ 100
Strongly outperforming
Debt / Equity
0.01
Debt-free
ROE
-73.15
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Founded in 2002 and headquartered in Geneva, Switzerland, Addex Therapeutics is a pharmaceutical company focused on developing oral drug treatments for neurological conditions. Its most advanced program, Dipraglurant, is being studied in clinical trials for recovery after stroke or brain injury and for managing movement problems caused by Parkinson's disease medication. The company is also advancing additional drug candidates targeting pain, anxiety, addiction, cough, and bladder conditions. Addex works alongside partners Janssen Pharmaceuticals and Indivior PLC to develop and bring these treatments to patients.
